Hormonal
Treatment with the selective beta3-adrenoceptor agonist CL 316,243 increases insulin-mediated glucose disposal (IMGD) and fat oxidation in lean human males, without altering energy expenditure or body weight.
Taking CL 316,243 (1,500 mg/day) for 8 weeks improves how your body handles insulin and increases the amount of fat you burn during the day, even without changing your total calorie burn or losing weight. This effect is strongest in lean individuals and depends on maintaining the drug's presence in your blood.
We conclude that treatment of lean male subjects with CL 316,243 increases insulin action and fat oxidation, both in a plasma concentration–dependent manner.
Why this rating
Randomized, placebo-controlled, double-blind study in humans, though with a small sample size (n=10 active) and short duration (8 weeks).
Source
Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective beta3-adrenoceptor agonist in humans.
C. Weyer et al. · Diabetes · 1998
DOI 10.2337/diabetes.47.10.1555
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →